EUVIMEDEUVIMED entdecken
Crossref

DFS70 Autoantibodies: Clinical Utility in Antinuclear Antibody Testing

Xavier Bossuyt

Clinical Chemistry · 2024

DOI: 10.1093/clinchem/hvad181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Xavier Bossuyt. Beteiligte Einrichtung: Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Autoimmune Diseases, Rheumatic Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Screening for antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells is helpful for the diagnosis and classification of ANA-associated rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, mixed connective tissue disease, systemic sclerosis, and inflammatory myopathies. The dense fine speckled (DFS) pattern is a special HEp-2 IIF pattern (produced by anti-DFS70 antibodies) because it is not associated with a specific medical condition and therefore can obfuscate interpretation. Content In this paper, detection methods for and clinical associations of anti-DFS70 antibodies are reviewed. Summary The target antigen of the antibodies that cause the DFS pattern is a 70 kDa protein (DFS70). Commercial methods that detect antibodies to full-length or truncated DFS70 are available for use in clinical laboratories (ELISA, chemiluminescence, dot/line blot). Anti-DFS70 can be found in (apparently) healthy individuals (with a higher frequency in young individuals and in females), in several (inflammatory) conditions and in malignancy. There is no clinical association that is well-established. Special attention (and critical reflection) is given to the observation that monospecific anti-DFS70 (i.e., in the absence of antibodies that are linked to ANA-associated rheumatic diseases) is rarely found in ANA-associated rheumatic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesRheumatic DiseasesFemaleHumansAntibodies, AntinuclearAutoantibodiesEnzyme-Linked Immunosorbent AssayTranscription FactorsMale

Substanzen

Antibodies, AntinuclearAutoantibodiesTranscription Factors

Autor:innen und Institutionen

  • Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology Research Group, KU Leuven, Leuven, Belgium.

Zitieren

APA

Bossuyt, X. (2024). DFS70 Autoantibodies: Clinical Utility in Antinuclear Antibody Testing. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad181

Vancouver

Bossuyt X. DFS70 Autoantibodies: Clinical Utility in Antinuclear Antibody Testing. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvad181

BibTeX
@article{Bossuyt2024,
  author = {Bossuyt, Xavier},
  title = {DFS70 Autoantibodies: Clinical Utility in Antinuclear Antibody Testing},
  journal = {Clinical Chemistry},
  year = {2024},
  doi = {10.1093/clinchem/hvad181}
}
Kostenlos starten →